Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Applied Genetic Technologies Corp    AGTC

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
3.75(c) 3.75(c) 3.65(c) 3.6(c) 3.65(c) Last
614 154 261 232 144 858 169 346 92 617 Volume
+5.63% 0.00% -2.67% -1.37% +1.39% Change
More quotes
Financials ($)
Sales 2018 36,0 M
EBIT 2018 -20,5 M
Net income 2018 -17,2 M
Debt 2018 -
Yield 2018 -
Sales 2019 31,8 M
EBIT 2019 -42,0 M
Net income 2019 -36,3 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 1,84x
Capi. / Sales2019 2,08x
Capitalization 66,0 M
More Financials
Company
Applied Genetic Technologies Corp. is a clinical-stage biotechnology company, which engages in the development of gene therapy products designed to transform the lives of patients with severe diseases in ophthalmology.Its product candidates are designed to treat X-linked retinoschisis,... 
More about the company
Surperformance© ratings of Applied Genetic Technologi
Trading Rating : Investor Rating :
More Ratings
Latest news on APPLIED GENETIC TECHNOLOGI
09/20 AGTC to Present at Upcoming Conferences
09/14 APPLIED GENETIC TECHNOLOGIES CORPORA : AGTC) Files An 8-K Results of Operations ..
09/13 APPLIED GENETIC TECHNOLOGIES CORP : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINA..
09/13 APPLIED GENETIC TECHNOLOGIES CORP (N : AGTC) reported earnings of ($0.18) per sh..
09/13 APPLIED GENETIC TECHNOLOGIES : posts 4Q loss
09/13 APPLIED GENETIC TECHNOLOGIES CORP : Results of Operations and Financial Conditio..
09/13 AGTC Announces Financial Results and Business Update for the Quarter and Fisc..
09/08 APPLIED GENETIC TECHNOLOGIES CORP - : Management's discussion and analysis of f..
09/06 APPLIED GENETIC TECHNOLOGIES : AGTC Appoints Matthew Feinsod, M.D. as Interim Ch..
09/05 AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/22Russell Investments Group Ltd. Has $394,000 Stake in Applied Genetic Technolo.. 
09/21Applied Genetic Technologies Corporation $AGTC Position Held by American Cent.. 
09/17$AGTC - Applied Genetic Technologies Corporation #AGTC Receives $14.63 Consen.. 
09/16Applied Genetic Technologies Corporation $AGTC Price Target Cut to $12.00  
09/16$AGTC - Applied Genetic Technologies Corporation #AGTC Price Target Cut to $1.. 
More tweets
Qtime:21
News from SeekingAlpha
09/14 Premarket analyst action - healthcare
09/13 Midday Gainers / Losers
09/13 Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q4 2017 Results - Earn..
09/13 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
09/13 Applied Genetic reports Q4 results
Chart APPLIED GENETIC TECHNOLOGI
Duration : Period :
Applied Genetic Technologi Technical Analysis Chart | AGTC | US03820J1007 | 4-Traders
Technical analysis trends APPLIED GENETIC TECHNOLOGI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 8,63 $
Spread / Average Target 136%
EPS Revisions
Managers
NameTitle
Susan B. Washer President, Chief Executive Officer & Director
William A. Sullivan Chief Financial Officer
Mark S. Shearman Chief Scientific Officer & Vice President
Matthew Feinsod Chief Medical Officer
James Rosen Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
APPLIED GENETIC TECHNOLOGIES CORP-60.96%66
AMGEN28.70%135 544
CELGENE CORPORATION24.61%112 572
GILEAD SCIENCES15.40%108 744
REGENERON PHARMACEUTICALS19.36%46 367
VERTEX PHARMACEUTICALS107.30%38 136